Search Result

Results for "

anti-HCV activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (16) Antibiotic (3) Apoptosis (1) Bacterial (1) Cyclophilin (3) DNA/RNA Synthesis (2) Fungal (1) Parasite (2) SARS-CoV (2)
By Research Areas:	Cancer (1) Infection (14) Inflammation/Immunology (3)
Click Chemistry:	Azide (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Click Chemistry

Targets Recommended: HCV HCV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0588

Deapioplatycodin D 1 Publications Verification	HCV	Infection
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

HY-N3519

Platycodin D3	HCV	Infection
Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

HY-N7765

Oenothein B	HCV Bacterial Apoptosis Fungal	Infection Inflammation/Immunology Cancer
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .

HY-115988

IMB-26	HCV	Infection
IMB-26 is a HCV inhibitor with an EC₅₀ of 2.1 μM. IMB-26 shows potent an anti-HCV activity .

HY-157291

Antiviral agent 44	Antibiotic HCV	Infection
Antiviral agent 44 (compound 7b) is an antiviral agent that has *anti-HCV* activity in vitro .

HY-112712

Cyclophilin inhibitor 1	Cyclophilin HCV	Infection
Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a K_d of 5 nM, shows effective anti-HCV activity, with an EC₅₀ of 98 nM for HCV 2a .

HY-146648

Cyclophilin inhibitor 3	Cyclophilin HCV	Infection
Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC₅₀ of 4.2 μM) .

HY-129057

2',5-Difluoro-2'-deoxycytidine	HCV	Infection
2',5-Difluoro-2'-deoxycytidine, compound 13, has potent anti-HCV activity and toxicity to ribosomal RNA (rRNA) .

HY-W555382

Pseudane IX 2-Nonylquinolin-4(1H)-one	HCV	Infection
Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-N3918

γ-Fagarine	HCV	Infection
γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-HCV activities with IC₅₀ of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer .

HY-115989

HCV-IN-38	HCV	Infection
HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .

HY-17470

Mizoribine 4 Publications Verification NSC 289637; HE 69	HCV SARS-CoV Antibiotic Parasite	Inflammation/Immunology
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-17470R

Mizoribine (Standard)	HCV SARS-CoV Antibiotic Parasite	Inflammation/Immunology
Mizoribine (Standard) is the analytical standard of Mizoribine. This product is intended for research and analytical applications. Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-125182

SMCypI C31	Cyclophilin HCV	Infection
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626	HCV DNA/RNA Synthesis	Infection
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride	HCV DNA/RNA Synthesis	Infection
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	311 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 311 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

311 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 311 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Deapioplatycodin D 1 Publications Verification	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields	HCV
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

Platycodin D3	Infection Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields	HCV
Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

Oenothein B	Infection Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	HCV Bacterial Apoptosis Fungal
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .

Mizoribine 4 Publications Verification NSC 289637; HE 69	Alkaloids Structural Classification Microorganisms Classification of Application Fields Other Alkaloids Source classification Inflammation/Immunology Disease Research Fields	HCV SARS-CoV Antibiotic Parasite
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

Pseudane IX 2-Nonylquinolin-4(1H)-one	Structural Classification Alkaloids Ketones, Aldehydes, Acids Source classification Ruta graveolens Linn. Rutaceae Quinoline Alkaloids Plants	HCV
Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

γ-Fagarine	Infection Alkaloids other families Classification of Application Fields Source classification Quinoline Alkaloids Plants Disease Research Fields	HCV
γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-HCV activities with IC₅₀ of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer .

Mizoribine (Standard)	Alkaloids Structural Classification Microorganisms Other Alkaloids Source classification	HCV SARS-CoV Antibiotic Parasite
Mizoribine (Standard) is the analytical standard of Mizoribine. This product is intended for research and analytical applications. Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

Cat. No.	Product Name		Classification

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626		Azide
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride		Azide
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks